Shots: Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates, discovered and developed under the agreement If Merck exercises its option, Skyhawk will receive an option fees, milestones and […]Read More
Shots: HitGen to receive upfront & milestones and will utilize its DNA-encoded library design technology to develop therapies for Sun Pharma’s SPARC targets The focus of the collaboration is to combine the SPARC’s research expertise with HitGen’s DELs based screening technology to develop therapies for serious medical conditions HitGen’s DELs is a platform for small […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
